Project – GC-MS Characterization and In Vitro Antidiabetic Potential of Azadirachta indica (Neem) Bark Extract Against α-Amylase and α-Glucosidase Enzymes

CHAPTER ONE

INTRODUCTION

1.1 Background of the Study

Diabetes mellitus is a chronic metabolic disorder characterized by persistent hyperglycemia resulting from defects in insulin secretion, insulin action, or both. It is one of the fastest-growing global health challenges, with increasing prevalence across both developed and developing countries. The disease is associated with serious long-term complications such as cardiovascular disorders, neuropathy, nephropathy, retinopathy, and impaired wound healing. According to the World Health Organization, diabetes is a leading cause of morbidity and mortality worldwide, and its burden continues to rise due to lifestyle changes, genetic predisposition, urbanization, and dietary transitions.

A major biochemical mechanism involved in the development of diabetes complications is postprandial hyperglycemia, which results from the rapid breakdown of carbohydrates into glucose in the digestive system. Two key enzymes responsible for this process are α-amylase and α-glucosidase. α-amylase breaks down complex carbohydrates into oligosaccharides, while α-glucosidase further hydrolyzes them into glucose for absorption into the bloodstream. Excessive activity of these enzymes leads to rapid elevation of blood glucose levels, thereby worsening diabetic conditions. Therefore, inhibition of these enzymes is a major therapeutic strategy for managing type 2 diabetes mellitus.

Conventional antidiabetic drugs such as acarbose and miglitol function by inhibiting carbohydrate-digesting enzymes. However, their use is often associated with side effects such as abdominal discomfort, bloating, diarrhea, and hypoglycemia. In addition, these synthetic drugs are expensive and may not be readily accessible in many developing regions. As a result, there is increasing interest in natural products as safer, more affordable alternatives for managing diabetes.

Medicinal plants have long been used in traditional medicine systems for the treatment of various diseases, including diabetes. These plants contain bioactive compounds such as alkaloids, flavonoids, tannins, saponins, terpenoids, and phenolic compounds, which exhibit antioxidant, anti-inflammatory, and antihyperglycemic properties. Scientific validation of these plants is essential to confirm their efficacy and safety for therapeutic use.

One such medicinal plant is Azadirachta indica, commonly known as neem. It is widely distributed in tropical and subtropical regions and has been used in traditional medicine for centuries due to its antimicrobial, anti-inflammatory, antimalarial, and antidiabetic properties. Different parts of the plant, including the leaves, seeds, bark, and roots, are known to possess medicinal value.

The bark of Azadirachta indica is particularly rich in bioactive compounds and has been traditionally used in the management of diabetes and other metabolic disorders. It contains a wide range of phytochemicals such as nimbin, nimbidin, azadirachtin, quercetin, flavonoids, and tannins, which are believed to contribute to its therapeutic effects. These compounds have been reported to exhibit antioxidant and glucose-lowering properties.

Gas Chromatography–Mass Spectrometry (GC-MS) is a powerful analytical technique used for the identification and characterization of volatile and semi-volatile compounds in plant extracts. GC-MS combines the separation ability of gas chromatography with the detection capability of mass spectrometry, making it highly suitable for phytochemical profiling. It allows researchers to identify bioactive compounds based on their mass spectra and retention times, which are compared with standard databases such as the NIST library (Sparkman, Penton, & Kitson, 2011).

GC-MS analysis of medicinal plants has revealed the presence of numerous bioactive compounds with pharmacological importance, including fatty acids, terpenoids, phenolic compounds, and sterols. These compounds have been associated with antidiabetic, antioxidant, and anti-inflammatory activities. The identification of such compounds in Azadirachta indica bark extract may provide scientific evidence for its traditional use in diabetes management.

In vitro antidiabetic studies involving enzyme inhibition assays have become important tools for screening medicinal plants. α-amylase and α-glucosidase inhibition assays are commonly used to evaluate the ability of plant extracts to regulate postprandial blood glucose levels. Plants that demonstrate strong inhibition of these enzymes are considered potential candidates for the development of natural antidiabetic drugs.

Given the increasing prevalence of diabetes and the limitations of synthetic drugs, there is a growing need to explore plant-based alternatives with fewer side effects. Azadirachta indica bark has been widely used in traditional medicine, but there is still limited scientific evidence regarding its detailed GC-MS phytochemical profile and its inhibitory effects on α-amylase and α-glucosidase enzymes. Therefore, this study seeks to fill this gap by investigating the GC-MS characterization and in vitro antidiabetic potential of Azadirachta indica bark extract.

1.2 Statement of the Problem

Diabetes mellitus continues to pose a significant global health burden due to its increasing prevalence and associated complications. Despite the availability of several synthetic antidiabetic drugs, the management of diabetes remains challenging due to drug side effects, high cost of treatment, and the need for lifelong medication. This situation has increased interest in medicinal plants as alternative therapeutic options.

Although Azadirachta indica is widely used in traditional medicine for the management of diabetes, there is still insufficient scientific validation of its antidiabetic potential, particularly at the level of enzyme inhibition. Most available studies have focused on its leaves, while the bark remains relatively underexplored in terms of detailed phytochemical characterization using advanced techniques such as GC-MS.

Furthermore, there is limited empirical data on the specific volatile bioactive compounds present in Azadirachta indica bark extract. Without proper GC-MS profiling, it is difficult to identify the compounds responsible for its medicinal effects. This lack of detailed phytochemical information limits the scientific understanding of its pharmacological potential.

In addition, there is inadequate experimental evidence on the inhibitory effects of Azadirachta indica bark extract on key carbohydrate-digesting enzymes such as α-amylase and α-glucosidase. Since these enzymes play a crucial role in postprandial hyperglycemia, the absence of sufficient data on enzyme inhibition creates a gap in understanding how the plant may contribute to diabetes management.

Therefore, the major problem addressed in this study is the lack of comprehensive scientific evidence on the GC-MS phytochemical profile and in vitro antidiabetic potential of Azadirachta indica bark extract against α-amylase and α-glucosidase enzymes. This study is designed to bridge this gap by providing detailed chemical characterization and biological evaluation of the bark extract.

1.3 Aim and Objectives of the Study

The aim of this study is to investigate the GC-MS characterization and in vitro antidiabetic potential of Azadirachta indica bark extract against α-amylase and α-glucosidase enzymes.

The specific objectives are to:

1. identify the volatile bioactive compounds present in Azadirachta indica bark extract using GC-MS analysis;
2. evaluate the in vitro α-amylase inhibitory activity of Azadirachta indica bark extract;
3. assess the in vitro α-glucosidase inhibitory activity of Azadirachta indica bark extract;
4. determine the relationship between the identified phytochemicals and antidiabetic activity of the extract.

1.4 Research Questions

1. What volatile bioactive compounds are present in Azadirachta indica bark extract as identified by GC-MS analysis?
2. Does Azadirachta indica bark extract inhibit α-amylase enzyme activity in vitro?
3. Does Azadirachta indica bark extract inhibit α-glucosidase enzyme activity in vitro?
4. How do the identified phytochemicals contribute to the antidiabetic activity of the extract?

1.5 Significance of the Study

This study will contribute to scientific knowledge by providing detailed GC-MS phytochemical profiling of Azadirachta indica bark extract. The identification of bioactive compounds will enhance understanding of its chemical composition and medicinal value.

The study will also provide empirical evidence on the in vitro antidiabetic potential of the bark extract, particularly its inhibitory effects on α-amylase and α-glucosidase enzymes. This may support the development of plant-based antidiabetic therapies.

Healthcare practitioners and traditional medicine users may benefit from the findings as it will validate the use of neem bark in diabetes management. The pharmaceutical industry may also utilize the results for drug development and formulation of herbal antidiabetic products.

1.6 Scope of the Study

This study is limited to GC-MS characterization and in vitro antidiabetic evaluation of Azadirachta indica bark extract. The study focuses specifically on α-amylase and α-glucosidase inhibitory assays. It does not include in vivo or clinical studies.

1.7 Operational Definition of Terms

GC-MS: Gas Chromatography–Mass Spectrometry used for identifying volatile compounds in plant extracts.

Antidiabetic Activity: The ability of a substance to reduce blood glucose levels or inhibit carbohydrate-digesting enzymes.

α-Amylase: An enzyme responsible for breaking down starch into simpler sugars.

α-Glucosidase: An enzyme that converts disaccharides into glucose in the small intestine.

Phytochemicals: Bioactive compounds found in plants with medicinal properties.

Project – GC-MS Characterization and In Vitro Antidiabetic Potential of Azadirachta indica (Neem) Bark Extract Against α-Amylase and α-Glucosidase Enzymes